OTC Markets Group Inc.

Class A Common Stock Alternative Reporting
OTCQX U.S. Premier

OTC Disclosure & News Service


OTC Markets Group Congratulates Trillium Therapeutics on NASDAQ Listing

Dec 22, 2014

OTC Disclosure & News Service

- OTC Markets Group Congratulates Trillium Therapeutics on NASDAQ Listing

OTC Markets Group Congratulates Trillium Therapeutics on NASDAQ Listing

PR Newswire

NEW YORK, Dec. 22, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM) congratulates Trillium Therapeutics Inc., an immuno-oncology company developing innovative therapies for the treatment of cancer, on its recent NASDAQ listing.  Trillium previously traded on OTCQX®, the best marketplace for established, global and growth companies operated by OTC Markets Group.

Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO  

Since joining OTCQX on May 20, 2013, Trillium Therapeutics' share price has risen 56%.  Likewise, the company's 30-day average daily dollar volume has increased 23-fold since it began trading on OTCQX. 

"We congratulate Trillium on its NASDAQ listing," said R. Cromwell Coulson, President and CEO of OTC Markets Group.  "Canadian, U.S. and other international companies choose OTCQX to grow their companies, increase their exposure to U.S. investors and, in some cases, to prepare for a U.S. stock exchange listing.  We are proud OTCQX has contributed to Trillium's achievement of this important milestone and wish the company all the best as it takes this next big step." 

Commented Dr. Niclas Stiernholm, President and CEO of Trillium, "OTCQX gave us valuable exposure to new investors in the U.S. and provided increased liquidity of our common shares in anticipation of our up-listing to NASDAQ."

OTCQX is the marketplace of choice for established global and growth companies that are looking to execute their business plans and graduate to a U.S. stock exchange listing.  Trillium is the ninth OTCQX company to up-list to a U.S. stock exchange this year.  Other OTCQX graduates include: BioPath Holdings Inc., Cellectar Biosciences Inc., CVSL Inc., Gulf Coast Ultra Deep Loyalty Trust, Immune Pharmaceuticals Inc., Kelso Technologies Inc., RXI Pharmaceuticals Corp. and Sphere 3D Corp.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities.  Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities.  We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace.  Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.  To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.

Subscribe to the OTC Markets RSS Feed

Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-congratulates-trillium-therapeutics-on-nasdaq-listing-300012799.html

SOURCE OTC Markets Group Inc.

Copyright © 2014 PR Newswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.